Document is current
Any future updates will be listed below
-
Authors
Liu, Li https://orcid.org/0000-0003-2566-7357
Bai, Jinxin
Zhou, Runhong
Ma, Yao
Zhou, Dongyan
Yuen, Terrence Tsz-Tai
Liu, Wenwu
Lai, Pok Man https://orcid.org/0000-0002-7967-8126
Yu, Wenjun
Duan, Jianxin
Ye, Jingjia
Liu, Xinhua
Gong, Ruomei
Kwan, Ka-Yi
Lee, Tsz Tung
Liu, Feifei
Du, Zhenglong
Wang, Pui https://orcid.org/0000-0003-0745-1130
Luo, Mengxiao
Yang, Dawei
Sze, Kong Hung https://orcid.org/0000-0002-0898-605X
Chu, Hin https://orcid.org/0000-0003-2855-9837
Chen, Zhiwei https://orcid.org/0000-0002-4511-2888
Liu, Gang https://orcid.org/0000-0001-5549-5686
-
Funding
Funding for this research was provided by:
Food and Health Bureau of the Government of the Hong Kong Special Administrative Region | Health and Medical Research Fund (24231222)
- License Information
-
More Information
Article History
Received: 29 April 2025
Accepted: 22 May 2026
First Online: 6 June 2026
Competing interests
: G.L., W.Y., L.L. and Z.C. are listed as inventors on a patent application filed by Ningbo Combireg Pharmaceutical Technology Co., Ltd. and The University of Hong Kong (provisional application number: CN202310158328.5, PCT/CN2023/077984), which covers the use of the MB-32 and its analogs in antiviral infection. G.L. is a co-founder of Ningbo Combireg Pharmaceutical Technology Co., Ltd., Zhejiang, PR China. The remaining authors declare no competing interests.
